Molecular Therapy AdvancesPathologyPeer-reviewed journal article
Voluntary Running Sustains the Correction of Inflammation-Related Gene Expression Conferred by AAV Gene Therapy in Mdx Mice
Claire YuaniD, Shelby E. HammiD, David L. MackiD, Jean-Baptiste Dupont, Robert W. GrangeiD
Abstract
Duchenne Muscular Dystrophy is a fatal disease characterized by persistent skeletal muscle degeneration, inflammation, and fibrosis. Gene therapy using an adeno-associated virus derived vector and a microdystrophin transgene is currently under investigation in patients but the impact of physical activity on long-term therapeutic outcome remains poorly understood. Recently, we reported 21-weeks of voluntary wheel running complemented the positive endurance and muscle function outcomes of gene therapy in mdx mice. In the present study, we performed a transcriptomic analysis of the gene expression changes associated with functional recovery in the diaphragm. RNA-Sequencing and bioinformatic analysis revealed 2881 dysregulated genes in untreated and unexercised mdx mice including inflammatory and fibrotic signaling pathways frequently affected in Duchenne Muscular Dystrophy patients. Among the dysregulated genes, 774 were rescued towards WT after adeno-associated virus microdystrophin injection. Importantly, 93% of the rescued genes were maintained by voluntary running, which indicates that physical exercise has no significant impact on the outcome of gene therapy in the mdx diaphragm. Our study provides vital information that could help guide DMD patient follow-up protocols after treatment with gene therapy.
- organism: mouse
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: statistical model
- approach: biophysical modeling
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 5th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Potential limitations of micro-dystrophin gene therapy for Duchenne muscular dystrophy
C. C. Hart, Y. i. Lee, … L. Sweeney·bioRxiv·Oct 2, 2022
- Axonopathy in Duchenne Muscular Dystrophy limits microdystrophin gene therapy efficacy
Aly Bourguiba, Maxime Gelin, … France Piétri‐Rouxel·bioRxiv·Aug 20, 2026
- Disease exacerbation by fibroblast inclusion in Duchenne Muscular Dystrophy MYOrganoids reveals limitations of microdystrophin therapeutic efficacy
L. Palmieri, L. Pili, … S. Albini·bioRxiv·Jul 26, 2023
- GDF5 modulation of MuSC pool as a potential therapeutic benefit for DMD
Christel Gentil, Aly Bourguiba, … France Piétri‐Rouxel·Molecular Therapy — Nucleic AcidsPeer-reviewed·Jul 7, 2026
- Periostin exon 17 skipping enhances the efficacy of local AAV-microdystrophin administration in a fibrotic model of Duchenne muscular dystrophy
Jessica Trundle, Alexis Boulinguiez, … Linda J. Popplewell·bioRxiv·Jan 21, 2025
- AAV and lentiviral transduction in Duchenne muscular dystrophy cardiomyocytes activate cell stress responses
Elaine C. Lai, Abiageal R. Keegan, Asuka Eguchi·bioRxiv·Aug 3, 2026